Hikal has reported total income of Rs. 381.4 crores during the period ended June 30, 2025
Currently focused on platform-related queries, elva.AI is the first step in ekincare’s broader roadmap
The Q-Switched Nd:YAG system is suitable for all skin types and offers versatility in treating dermal and epidermal pigmentation
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Subscribe To Our Newsletter & Stay Updated